Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2012 4
2013 2
2019 3
2020 7
2021 9
2022 12
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. McGarvey LP, et al. Among authors: schelfhout j. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. Lancet. 2022. PMID: 35248186 Clinical Trial.
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Birring SS, Dicpinigaitis PV, Smith JA, Morice AH, McGarvey LP, Pavord ID, Nguyen AM, Schelfhout J, Li Q, Iskold B, Green SA, Philip G, Muccino DR, La Rosa C. Birring SS, et al. Among authors: schelfhout j. Am J Respir Crit Care Med. 2023 Jun 1;207(11):1539-1542. doi: 10.1164/rccm.202211-2128LE. Am J Respir Crit Care Med. 2023. PMID: 36996347 Free PMC article. No abstract available.
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA, Birring SS, Dicpinigaitis PV, McGarvey LP, Morice AH, Pavord ID, Satia I, Green S, Iskold B, La Rosa C, Li Q, Martin Nguyen A, Schelfhout J, Muccino D. Smith JA, et al. Among authors: schelfhout j. Lung. 2022 Aug;200(4):423-429. doi: 10.1007/s00408-022-00553-y. Epub 2022 Jul 27. Lung. 2022. PMID: 35895098 Free PMC article. Clinical Trial.
Chronic cough in Germany: results from a general-population survey.
Virchow JC, Li VW, Fonseca E, Salmen H, Martin A, Brady J, Jannowitz C, Schelfhout J. Virchow JC, et al. Among authors: schelfhout j. ERJ Open Res. 2022 Jan 10;8(1):00420-2021. doi: 10.1183/23120541.00420-2021. eCollection 2022 Jan. ERJ Open Res. 2022. PMID: 35036416 Free PMC article.
Prevalence and Burden of Chronic Cough in the United States.
Meltzer EO, Zeiger RS, Dicpinigaitis P, Bernstein JA, Oppenheimer JJ, Way NA, Li VW, Boggs R, Doane MJ, Urdaneta E, Weaver JP, Schelfhout J, Fonseca E. Meltzer EO, et al. Among authors: schelfhout j. J Allergy Clin Immunol Pract. 2021 Nov;9(11):4037-4044.e2. doi: 10.1016/j.jaip.2021.07.022. Epub 2021 Jul 29. J Allergy Clin Immunol Pract. 2021. PMID: 34333189
46 results